Literature DB >> 24139208

Adenomatous polyposis coli gene involvement in ileal enterochromaffin cell neuroendocrine neoplasms.

Lorena Bottarelli1, Cinzia Azzoni, Silvia Pizzi, Tiziana D'Adda, Enrico Maria Silini, Cesare Bordi, Guido Rindi.   

Abstract

The adenomatous polyposis coli gene is a key tumor suppressor gene. Alterations in this gene have been found in most sporadic colon cancers; associated with familial adenomatous polyposis; and found in neoplasms of other organs, such as the liver, stomach, lung, breast, and cerebellar medulloblastoma. In the heterogeneous group of neuroendocrine neoplasms of the gastrointestinal tract, the involvement of adenomatous polyposis coli is debated, and only occasional reports found adenomatous polyposis coli alterations in foregut and midgut neuroendocrine neoplasms, with adenomatous polyposis coli mutations only in the latter. To elucidate the penetrance of adenomatous polyposis coli alterations in ileal neuroendocrine neoplasms, we performed DNA fragment analysis (loss of heterozygosity for 5q22-23 and 5q23) and sequencing on the mutation cluster region of the adenomatous polyposis coli gene on 30 ileal enterochromaffin cell neuroendocrine neoplasms. Adenomatous polyposis coli gene mutations were detected in 23% of cases (7/30); in particular, 57% were missense and 14%, nonsense/frameshift, all novel and different from those reported in colorectal or other cancers. Loss of heterozygosity analysis demonstrated a deletion frequency of 15% (4/27). No association was found with features of tumor progression. Our observations support the involvement of somatic adenomatous polyposis coli alterations in tumorigenesis of ileal enterochromaffin cell neuroendocrine neoplasms; the mechanisms of adenomatous polyposis coli gene inactivation appear to be different from those reported in other tumor types.
© 2013.

Entities:  

Keywords:  APC; Allelic losses; Ileal neuroendocrine neoplasms; Mutation; Polymorphism

Mesh:

Substances:

Year:  2013        PMID: 24139208     DOI: 10.1016/j.humpath.2013.06.019

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  9 in total

1.  Regulatory single nucleotide polymorphisms (rSNPs) at the promoters 1A and 1B of the human APC gene.

Authors:  Marina Yu Matveeva; Elena V Kashina; Vasily V Reshetnikov; Leonid O Bryzgalov; Elena V Antontseva; Natalia P Bondar; Tatiana I Merkulova
Journal:  BMC Genet       Date:  2016-12-22       Impact factor: 2.797

2.  Immunohistochemical analysis of the Wnt/β-catenin signaling pathway in pancreatic neuroendocrine neoplasms.

Authors:  Vivian Weiss; Julie Dueber; Jesse P Wright; Justin Cates; Frank Revetta; Alexander A Parikh; Nipun B Merchant; Chanjuan Shi
Journal:  World J Gastrointest Oncol       Date:  2016-08-15

3.  Primary high-grade neuroendocrine carcinoma emerging from an adenomatous polyp in the setting of familial adenomatous polyposis.

Authors:  Claire J Detweiler; Diana M Cardona; David S Hsu; Shannon J McCall
Journal:  BMJ Case Rep       Date:  2016-02-16

Review 4.  Targeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical strategies and future targets.

Authors:  E T Aristizabal Prada; C J Auernhammer
Journal:  Endocr Connect       Date:  2017-11-16       Impact factor: 3.335

5.  Mutational and copy number asset of primary sporadic neuroendocrine tumors of the small intestine.

Authors:  Michele Simbolo; Caterina Vicentini; Andrea Mafficini; Matteo Fassan; Serena Pedron; Vincenzo Corbo; Luca Mastracci; Borislav Rusev; Corrado Pedrazzani; Luca Landoni; Federica Grillo; Sara Cingarlini; Guido Rindi; Claudio Luchini; Aldo Scarpa; Rita T Lawlor
Journal:  Virchows Arch       Date:  2018-09-16       Impact factor: 4.064

6.  Molecular prognostic factors in small-intestinal neuroendocrine tumours.

Authors:  K G Samsom; L M van Veenendaal; G D Valk; M R Vriens; M E T Tesselaar; J G van den Berg
Journal:  Endocr Connect       Date:  2019-07       Impact factor: 3.335

7.  Inhibition of Wnt/β-Catenin Signaling in Neuroendocrine Tumors in vitro: Antitumoral Effects.

Authors:  Xi-Feng Jin; Gerald Spoettl; Julian Maurer; Svenja Nölting; Christoph Josef Auernhammer
Journal:  Cancers (Basel)       Date:  2020-02-04       Impact factor: 6.639

Review 8.  Clinical Features, Management, and Molecular Characteristics of Familial Small Bowel Neuroendocrine Tumors.

Authors:  James Y Lim; Rodney F Pommier
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-26       Impact factor: 5.555

Review 9.  From microbiota toward gastro-enteropancreatic neuroendocrine neoplasms: Are we on the highway to hell?

Authors:  Giovanni Vitale; Alessandra Dicitore; Luigi Barrea; Emilia Sbardella; Paola Razzore; Severo Campione; Antongiulio Faggiano; Annamaria Colao; Manuela Albertelli; Barbara Altieri; Filomena Bottiglieri; Federica De Cicco; Sergio Di Molfetta; Giuseppe Fanciulli; Tiziana Feola; Diego Ferone; Francesco Ferraù; Marco Gallo; Elisa Giannetta; Federica Grillo; Erika Grossrubatscher; Elia Guadagno; Valentina Guarnotta; Andrea M Isidori; Andrea Lania; Andrea Lenzi; Fabio Lo Calzo; Pasquale Malandrino; Erika Messina; Roberta Modica; Giovanna Muscogiuri; Luca Pes; Genoveffa Pizza; Riccardo Pofi; Giulia Puliani; Carmen Rainone; Laura Rizza; Manila Rubino; Rosa Maria Ruggieri; Franz Sesti; Mary Anna Venneri; Maria Chiara Zatelli
Journal:  Rev Endocr Metab Disord       Date:  2020-09-15       Impact factor: 9.306

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.